Latest revision as of 01:27, 30 September 2014

Tufts iGEM 2014

Home

Team

Official Team Profile

Project

Parts

Modeling

Notebook

Safety

Attributions

Summaries

Robust biofilm formation using a cyclic-di-GMP aptamer and investigating ethics and applications of engineered bactiophage

A long, noncoding massively expressed regulatory RNA (merRNA) discovered in Bdellovibrio bacteriovorus is present in high levels during its dormant phase. The merRNA is believed to sequester cyclic-di-GMP, much like a sponge. Since cyclic-di-GMP is a second messenger for various cellular functions, including motility and biofilm formation, the Tufts iGEM team introduced this merRNA sequence into E. coli. Constitutive expression of this merRNA transcript was shown to increase biofilm formation. This property can be useful in microbe-based approaches to environmental remediation. Earlier designs for phage delivery of the merRNA to disrupt biofilms inspired an investigation into the policy surrounding engineered bacteriophage. Tufts iGEM will be convening a panel of experts from various disciplines to put forth recommendations for the responsible use of phage in therapeutic and industrial applications. A proposal will be drafted for a silk bandage containing a phage cocktail which can prevent and treat infection by antibiotic-resistant bacteria.

Ribosponge Project Description:

We have devised a method to introduce a DNA sequence which encodes an RNA aptamer (i.e. - an oligonucleotide sequence which binds to a specific molecule) into a non-pathogenic E. coli strain. We have dubbed this RNA aptamer a “ribosponge” due to its unique mode of action. The ribosponge binds cyclic di-GMP, a secondary intracellular messenger which signals bacteria to enter a persistent or biofilm state. The signal is universal among many species such as E. coli, P. aeruginosa, and M. tuberculosis. Blocking the signal of c-di-GMP by binding it with an aptamer could prevent the persistent state in these and other pathogens. In order to ferry the sequence encoding the aptamer from our non-pathogenic E. coli into other bacteria of the same species, we plan on using an M13 phage which does not kill the bacteria. The project has also inspired our collaboration with the Rathneau Institute and SYNENERGENE as we look at the feasability of developing ribosponge into a product, and examine the regulatory, legal, and ethical challenges of packing it into a bacteriophage.

Backgrounds

Methods

Sponge Lab Notebook

@@ Line 28: / Line 28: @@
 <td style="border:2px solid #0099FF;" align="center"  height ="45px"  bgColor=black>
-<a href="https://igem.org/Team.cgi?year=2014&team_name=Tufts"style="color:#0099FF"> Official Team Profile </a></td>
+<a href="https://igem.org/Team.cgi?year=2014&team_name=Tufts"style="color:#0099FF"target="_blank"> Official Team Profile </a></td>
 <td style="border:2px solid #0099FF" align="center"  height ="45px" bgColor=black>

Team:Tufts/Project

From 2014.igem.org